ASTRIDE Study (Extensive Stage)
302 Study (Limited Stage)
What is a clinical trial?
Clinical trials are research studies that test new medicines (or current medicines for different conditions), new technology, and new procedures, to find better ways to treat diseases, as well as how to better prevent or diagnose diseases.
Who can participate in these clinical studies?
Adults (people 18 and older) who have either extensive-stage small cell lung cancer or limited-stage small cell lung cancer may qualify for either the ASTRIDE Study or the 302 Study.
Can I change my mind about participating in the study?
If you start the study, you can leave at any time, and you can discuss different treatment options with your oncologist (cancer doctor). However, if you choose not to participate, and you begin treatment, you cannot join the study later on.
Will I know what study medication I am taking?
It depends. Participants enrolled in the ASTRIDE Study for extensive-stage small cell lung cancer will be told if they are taking the study drug, serplulimab, or if they are taking atezolizumab. Participants enrolled in the 302 Study for limited-stage small cell lung cancer will not be told if they’re taking serplulimab with chemotherapy and radiation, or chemotherapy and radiation alone.
Can patients with non-small cell lung cancer participate in either clinical study?
No. The ASTRIDE Study and 302 Study are only for participants with small cell lung cancer, which accounts for about 15% of all lung cancers.
How long will I be in the clinical study?
Participants can stay in the study until their cancer gets worse, or until their doctor recommends exiting the study. If you leave the study, we may still follow your progress to gather more information about the safety and effectiveness of serplulimab.
Are there side effects from the study drug?
In previous clinical studies for serplulimab, the side effects were generally manageable, and there was not much difference between patients in the group taking serplulimab and patients taking a placebo.1
However, all patients in both studies will be taking chemotherapy, and patients in the 302 Study for limited-stage small cell lung cancer will also be receiving radiation therapy. Both chemotherapy and radiation have their own side effects.
Ask your oncologist for more information about the side effects associated with the treatments you will be receiving.